Individualized Medicine Pharmacogentics

Right Dose. Right Time.Right Dose. Right Time.First Time.First Time.

Susan Kolyno, BA, CMA, Susan Kolyno, BA, CMA, Vantari Laboratory RepresentativeVantari Laboratory Representativemedrefer1@gmail.commedrefer1@gmail.com

Why PharmacogenticsAvoidable Medical Problem

700,000

600,000

500,000

400.000

300.000

200,000

100,000

Heart Cancer Stroke RX Car Accidents

HEART CANCER STROKE RX CAR CRASHES

0

2

4

6

8

10

12

Series8

Series7

Column 3

Column 2

Column 1

Series3

Series2

Series1

2.2 MILLION

severe adverse drug reactions per year

PATIENTS ARE AT RISK

100,000 deaths per year

By PROPERLY PRESCRIBED MEDICATIONS

COST LEADER for Mal-Practice

Treatment Failures Prevalent in Disease statesPrevalent in Disease states

“Keeping in Step” “Do No Harm” Cancer 75%

Alzheimers 70%

Arthritis 50%

Diabetic 43%

Asthma 40%

Anti-depressants 38%

GENETIC differences in metabolism = Treatment Failure

Poly-Pharmacy AlzheimerComplications in Prescribing

Patients Taking More than 3 Medications

AT RISK - 40% are over 65

More thanMore than 75% 75% of the population have documented genetic variations that of the population have documented genetic variations that increase their risk for ADR's. increase their risk for ADR's.

Medicines most commonly associated with ADR's areMedicines most commonly associated with ADR's are 8X8X more likely to go more likely to go through pathways with genetic variants. through pathways with genetic variants.

Avoiding ADR'sGetting Right the First Time

PharmacogeneticsPharmacogenetics is the is the understanding of how the genetic understanding of how the genetic variation alters drug response. variation alters drug response. CytochromesCytochromes (CYPs) (CYPs) are the are the metabolic factories in the liver and metabolic factories in the liver and intestines. intestines.

Poor Metabolizers:Poor Metabolizers: Reach maximum Reach maximum levels very quicklylevels very quickly Intermediate Intermediate Metabolizers:Metabolizers: Half the highway is shut Half the highway is shut down, a patient can still metabolize but it is down, a patient can still metabolize but it is very difficult. very difficult. Ultra MetabolizersUltra Metabolizers: : Have Have additional pathways, these patients never additional pathways, these patients never reach therapeutic effect. reach therapeutic effect. Normal Normal Metabolizers:Metabolizers: Have both roads open and Have both roads open and metabolize close to normal.metabolize close to normal.

Changing the PatternWill YOU make the Difference?

Interactions involve Interactions involve cytochromes: 2C9 CYP2D6, cytochromes: 2C9 CYP2D6, CYP2C19, and CYP3A4 CYP2C19, and CYP3A4 Individual Individual DNA varies in DNA varies in Medications and Metabolism Medications and Metabolism

Impacting more patients than Impacting more patients than Common Genetic testing. Common Genetic testing.

MEDICATION MANAGEMENT MEDICATION MANAGEMENT BASED ON PATIENT BASED ON PATIENT METABOLISM METABOLISM

..More than 100 medications have drug to gene interactions More than 100 medications have drug to gene interactions

and are identified in the FDA packet and black box labelsand are identified in the FDA packet and black box labels

Why Vantari?Focus IS On the Patient

Vantari centers it's approach on testing & hard copy results FOR the PATIENT.

Referencing our Partner CPIC, an independent consortium and 2014 date publication for physician results & poly- pharmacy recommendations.

Highly complex CLIA certified.

Getting Started No Cost Assistance

Complete the simple form with your Vantari representative:

SET A DATE MONTHLY - Book 10 -15 patients for an OFF day for screening.

Representative will assist and follow up with billing or office management.

NO OUT OF POCKET

Compliance Regulated – Request Clinical Studies, Dossiers, access to CPIC.

Test Results - Insurance3-5 Days

Your screening tests and follow-up Your screening tests and follow-up are billable. are billable.

Contact

I can provide case studies, clinical data and insurance information on pharmacogentics and the impact upon the medical profession that is NOW changing prescribing methods rapidly.

Please feel free to contact me with any questions or individualized studies geared to your practice.

YOUR VANTARI REPRESENTATIVE:

Susan Kolyno 404-989-5084 Website: www.medreferrals.net

RIGHT DOSE. RIGHT TIME. FIRST TIME

YOUR Vantari TeamAccrediations

Nick G. Arroyo -Chief Executive Officer - Nick Arroyo earned his Bachelor of Science Degree in Molecular Biosciences and Biotechnology from Arizona State University. He began his career working in research in the Department of Gene and Cellular Therapy at the Arizona Heart Institute where he helped to develop an investigational stem cell therapy for heart failure and was responsible for the cell manufacturing processes required for obtaining FDA approval for phase I clinical trial.

Sean Parrish - Chief Operating Officer - Sean Parrish is co-founder of Vantari Genetics and our Chief Operating Officer. Mr. Parrish's responsibilities encompass national commercialization of our molecular diagnostics services across the entire value chain from test inception through customer development and product distribution. Mr. Parrish has been part of the development, launch and marketing strategy for SimpleCF™, Vantari's cystic fibrosis carrier screening test. Mr. Parrish obtained a Bachelor of Science degree from the University of Arizona.

Shaun R. Opie, PhDChief Science Officer - Dr. Opie holds a PhD in Biomedical Sciences/Molecular Genetics. He led all laboratory operations for an investigator initiated Phase I clinical trial using stem cells to treat cardiac disease and helped develop a proprietary cardiovascular disease gene data set for a publicly traded genomics company. In addition to clinical trial design and management for FDA regulated investigational new drugs and devices, Dr. Opie has over 10 years of operations management directing major collaborations with industry and academic partners in molecular diagnostics research and development. He has held adjunct faculty appointments in bioengineering and has numerous publications in peer reviewed medical journals and textbooks.

Phil Lamb -Senior Advisor - Phil has a track record of successfully leading growth businesses into highly responsive, client-focused service organizations. He provides legal, financial, and strategic advice to the Vantari Genetic team. In addition to his role with Vantari Genetics, he is also a principal in Infinity Software Solutions, a leading Human Resources Information System (HRIS). Phil received his J.D. from Harvard Law.

Thank You

Right Dose. Right Time.Right Dose. Right Time.First Time.First Time.

Preventative Patient CarePreventative Patient Care

Susan Kolyno, Account Manager, Vantari LaboratoriesSusan Kolyno, Account Manager, Vantari Laboratories423-790-7306 or 404-989-5084423-790-7306 or 404-989-5084